Singapore markets closed

Organon & Co. (OGN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
31.16+0.46 (+1.50%)
As of 12:26PM EST. Market open.

Organon & Co.

30 Hudson Street
Jersey City, NJ 07302
United States
551 430 6000

IndustryDrug Manufacturers—General
Full-time employees9,000

Key executives

NameTitlePayExercisedYear born
Mr. Kevin AliCEO & DirectorN/AN/A1960
Mr. Matthew M. WalshChief Financial OfficerN/AN/A1967
Ms. Rachel A. StahlerChief Information OfficerN/AN/A1976
Ms. Jennifer HalchakVP of Investor RelationsN/AN/AN/A
Ms. Deborah H. TelmanGen. Counsel & Company Sec.N/AN/A1966
Mr. Aaron FalcioneChief HR OfficerN/AN/A1971
Ms. Susanne Gabriele FiedlerChief Commercial OfficerN/AN/A1968
Dr. Sandra Milligan J.D., M.D.Head of R&DN/AN/A1964
Mr. Joseph T. Morrissey Jr.Head of Manufacturing & SupplyN/AN/A1965
Mr. Vittorio NisitaHead of Global Bus. ServicesN/AN/A1968
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.

Corporate governance

Organon & Co.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.